IL107066A - Pharmaceutical compositions containing diaminobenzenedisulfonic acid sodium salt oligomers for antagonizing inositol 1, 4, 5-triphosphate - Google Patents
Pharmaceutical compositions containing diaminobenzenedisulfonic acid sodium salt oligomers for antagonizing inositol 1, 4, 5-triphosphateInfo
- Publication number
- IL107066A IL107066A IL107066A IL10706693A IL107066A IL 107066 A IL107066 A IL 107066A IL 107066 A IL107066 A IL 107066A IL 10706693 A IL10706693 A IL 10706693A IL 107066 A IL107066 A IL 107066A
- Authority
- IL
- Israel
- Prior art keywords
- inositol
- triphosphate
- oligomers
- pharmaceutical compositions
- antagonizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Oligomers of formula (I) have been demonstrated to be effective antagonists of inositol 1,4,5-triphosphate (IP3) by competitively vying with IP3 for binding sites. By competitively inhibiting the activity of IP3, the oligomers of this invention can modulate the release of intracellular calcium and elicit the resultant physiological effects.
[WO9407507A1]
Description
107066/2 PHARMACEUTICAL COMPOSITIONS CONTAINING DIAMINO-BENZENEDISULFONIC ACID SODIUM SALTS OLIGOMERS FOR ANTAGONIZING INOSITOL 1 ,4,5-TRIPHOSPHATE , ,1 "pio ira 1213 niTJinn'? π",]ΐ9'?ιοιτ]Τ]αΊ]ιηκΊτ 4A ABSTRACT OF THE DISCLOSURE Oligomers of the formula have been demonstrated to be effective antagonists of inositol 1,4,5-trisphosphate (IP3) by competitively vying with IP3 for binding sites. By competitively inhibiting the activity of IP3, the oligomers of this invention can modulate the release of intracellular calcium and elicit the resultant physiological effects.
BACKGROUND OF THE INVENTION This application relates to a series of diamino benzenedisulfonic acid oligomers that have demonstrated an affinity for the receptor sites of inositol 1.4,5-triphosphate (IP3) and are, therefore useful in diminishing the bioactivity of IP3. especially with regard to its effect on the release of intracellular calcium ions.
DESCRIPTION OF THE PRIOR ART The diamino benzenedisulfonic acid oligomers demonstrating utility as IP3 antagonists according to this invention are described in detail in the European Patent Application published January 22, 1992 under Publication No. 0467185 AZ and IL98761. In that publication, the oligomers of the present invention were described as having utility in the diagnosis and/or treatment of AIDS and AIDS related complex.
SUMMARY OF THE INVENTION The invention herein disclosed relates to pharmaceutical compositions for inhibiting the activity of inositol 1 ,4, 5-triphosphate (IP3) by occupying the receptor sites specific to IP3 with a compound of the formula: -2- wherein n is a whole number selected from the range of 5 to 20 inclusive and the pharmaceutically acceptable salts thereof .
DETAILED DESCRIPTION OF THE INVENTION Inositol I, 4, 5-triphosphate (IP3) is a naturally occurring and active component of animal physiology. It is formed intracellularly upon the activation of cell-surface receptors linked to the enzyme phospholipase C. Once generated in sufficient quantities, IP3 acts to stimulate the release of calcium ions from storage organelles within the cell. In this role IP3 is characterized as a "second messenger". Depending upon the type of cell, the calcium released by IP3 functions to stimulate a variety of physiologic processes such as smooth muscle contraction, histamine secretion and the hyperpolarization of nerve cells. Any compound or agent that can promote or interfere with the function of IP3, will promote or interfere with the generation of calcium ions and thereby elicit predictable pharmacological effects.
The process by which IP3 releases calcium ions begins with the binding of IP3 to a specific receptor protein located on an intracellular calcium storage compartment located typically on the endoplasmic reticulum. This receptor protein has been cloned and has been shown to form a calcium "channel" with unique structural properties when bound to IP3. Therefore, when IP3 binds with its receptor, a calcium channel is opened causing the release of calcium stored in the cell's endoplasmic reticulum. In turn, the -3-released calcium will elicit the appropriate cellular response.
Heretofore, the only verified potent antagonist of the IP3 receptor was heparin, a complex glycosaminoglycan. The diamino benzenedisulfonic acid oligomers of this invention also appear to antagonize the effects of IP3 by competing for the receptor site. In most cases, these compounds are more effective than heparin and demonstrate fewer secondary effects. In addition to providing utility as laboratory "tools" in evaluating the therapeutic potential of other IP3 receptor antagonists, the oligomers of this invention would also be administered to modulate IP3-induced calcium release and have a salutary effect on any number of disorders that are caused or exacerbated by an inordinately productive IP3 second messenger pathway.
EXPERIMEN ALS Measurement of IP3 Binding Cerebella from male Sprague-Dawley rats (200 g) were homogenized in 30 volumes of ice-cold buffer A (50 mM Tris, 1 mM dithiothreitol, 1 mM EDTA, pH 7.7 with HC1) with a polytron (setting 9 for 10 seconds). The tissue is then washed twice by centrifugation (20,000 x g, 15 minutes; Sorvall 28-S., SS-34 rotor) and resuspended in 30 volumes of ice-cold buffer A.
For the binding assays, 1.5 ml eppendorf tubes containing 50 μΐ of test compound (made up as a lOx stock in water) or water, 50 μΐ [3H] IP3 (17Ci/mmol; Dupont-NEN; usually made as a 25 nM (lOx) stock solution in buffer), and 350 μΐ of buffer B (buffer A with pH adjusted to 8.4) on ice. Tubes for non-specific binding also contained 50 μΐ of non-radioactive IP3 (100 μΜ stock (lOx); final concentration 10 μΜ) , with an appropriate reduction in the volume of buffer B. Reactions were initiated by the addition of 50 μΐ tissue to make the final volume 500 μΐ, -4-followed by vortex mixing. Samples were incubated on ice for 10 minutes and then were centrifuged (14,000 x g) in a microfuge (Eppendorf model 5415) for 5 minutes followed by aspiration of the supernatant fraction. The tissue pellets were solubilized overnight in 100 yl of Protosol (Dupont-NEN) . After solubilization, 73 μΐ of glacial acetic acid were added to decrease chemiluminescence, and the mixture was transferred to scintillation vials. To these vials was added 7 ml of Ecoscint-A (National Diagnostics) and the radioactivity determined by liquid scintillation spectrophotometry.
Specific binding was defined as the difference between total binding (radioactivity in the absence of test compound and cold IP3) and non-specific binding (radioactivity in the absence of test compound but in the presence of cold IP3). This number was taken as 100% specific binding. Data points obtained with the test compounds were fit by a computer program (GraphPad-InPlot ) to determine their inhibitory potency. The inhibitory potencies of the test compounds were expressed as the concentration of compound that produces 50% inhibition of specific binding (the IC50 value).
The binding data are presented in Table 1 and demonstrate that compounds within the scope of the present invention effectively compete for [3H] IP3 binding sites in rat cerebellar membranes. The compound identified as DL 102,869 was the most potent competitor for binding with an IC50 of 50 nM, whereas low molecular weight heparin (5100 MW) had an IC50 of 74 nM. MDL 102,869 is the compound according to the claimed invention wherein n = 15.
The potency for binding also seems to correlate with the ability to antagonize IP3~induced calcium ion release. Thus, 1 and 3 μΜ of MDL 102,869 inhibited calcium ion release by 42 and 100%, respectively (see Fig. 1), whereas -5- 10 μ of heparin inhibited release by 90%. MDL 101,828, which had an IC50 binding of 104 nM, inhibited IP3~induced calcium ion release by 72% at 3 micro moles. MDL 101,828 is the compound according to the claimed invention wherein n = 9.
TABLE 1 The tracing of Fig. 1, dramatically illustrates the inhibition data set forth in the third column of Table 1 The y-axis represents the concentration of free calcium ions in arbitrary units. The tracing shows that two successive additions of 0.1 μΜ of IP3 stimulated similar amounts of calcium ion release from cerebellar microsomes. The addition of 1 μΜ of MDL 102,869 stimulated a small increase of calcium ion for unknown reasons. In the presence of 102,869, however, calcium ion release stimulated by 0.1 μΜ of IP3 was inhibited by 42%. This inhibition was overcome by the addition of 1 μΜ of IP3, consistent with competitive antagonism by MDL 102,869. 107066/2 -6-
Claims (3)
1.A pharmaceutical composition for inhibiting the activity of inositol 1 , 4, 5-trisphosphate by occupying a receptor site specific to inositol 1 ,4,5-trisphosphate containing an effective quantity of a compound of the formula wherein n is a whole number within the range of 5-20 and the pharmaceutically acceptable salts thereof.
2. he composition of claim 1 wherein the oligomer n is 9.
3. The composition of Claim 1 wherein the oligomer n is 15.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95239392A | 1992-09-28 | 1992-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL107066A0 IL107066A0 (en) | 1993-12-28 |
IL107066A true IL107066A (en) | 1998-01-04 |
Family
ID=25492868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL107066A IL107066A (en) | 1992-09-28 | 1993-09-22 | Pharmaceutical compositions containing diaminobenzenedisulfonic acid sodium salt oligomers for antagonizing inositol 1, 4, 5-triphosphate |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0661982A1 (en) |
JP (1) | JPH08502068A (en) |
KR (1) | KR950703347A (en) |
AU (1) | AU670962B2 (en) |
CA (1) | CA2145681A1 (en) |
HU (1) | HUT70192A (en) |
IL (1) | IL107066A (en) |
MX (1) | MX9305933A (en) |
NO (1) | NO951163L (en) |
NZ (1) | NZ256178A (en) |
TW (1) | TW260663B (en) |
WO (1) | WO1994007507A1 (en) |
ZA (1) | ZA936978B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2978995A (en) * | 1994-06-30 | 1996-01-25 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Methods for treating cell proliferative disorders by modulating signal transduction |
US5780483A (en) * | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
WO1996025157A1 (en) | 1995-02-17 | 1996-08-22 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
US6083920A (en) * | 1995-12-21 | 2000-07-04 | Ayurcore, Inc. | Compositions for modulating intracellular inositol trisphosphate concentration |
US6005008A (en) * | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US6211373B1 (en) | 1996-03-20 | 2001-04-03 | Smithkline Beecham Corporation | Phenyl urea antagonists of the IL-8 receptor |
US6262113B1 (en) | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
AU3499497A (en) | 1996-06-27 | 1998-01-14 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
TR199802694T2 (en) * | 1996-06-27 | 1999-03-22 | Smithkline Beecham Corporation | IL-8 resept�r kar��tlar� |
ATE358486T1 (en) * | 2000-11-09 | 2007-04-15 | Contrimmune Biotechnology Inc | USE OF XESTOSPONGIN C TO TREAT OR PREVENT HIV INFECTION |
CA2857374A1 (en) | 2011-09-02 | 2013-03-07 | The Trustees Of Columbia University In The City Of New York | Camkii, ip3r, calcineurin, p38 and mk2/3 inhibitors to treat metabolic disturbances of obesity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB781479A (en) * | 1953-08-27 | 1957-08-21 | Ciba Ltd | New polyureas and process for making them |
US5276182A (en) * | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
-
1993
- 1993-08-30 CA CA002145681A patent/CA2145681A1/en not_active Abandoned
- 1993-08-30 JP JP6509054A patent/JPH08502068A/en active Pending
- 1993-08-30 EP EP93921252A patent/EP0661982A1/en not_active Ceased
- 1993-08-30 HU HU9500891A patent/HUT70192A/en unknown
- 1993-08-30 KR KR1019950701166A patent/KR950703347A/en not_active Application Discontinuation
- 1993-08-30 WO PCT/US1993/008168 patent/WO1994007507A1/en not_active Application Discontinuation
- 1993-08-30 NZ NZ256178A patent/NZ256178A/en unknown
- 1993-08-30 AU AU48417/93A patent/AU670962B2/en not_active Ceased
- 1993-09-21 ZA ZA936978A patent/ZA936978B/en unknown
- 1993-09-22 IL IL107066A patent/IL107066A/en not_active IP Right Cessation
- 1993-09-22 TW TW082107787A patent/TW260663B/zh active
- 1993-09-27 MX MX9305933A patent/MX9305933A/en unknown
-
1995
- 1995-03-27 NO NO951163A patent/NO951163L/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW260663B (en) | 1995-10-21 |
AU4841793A (en) | 1994-04-26 |
WO1994007507A1 (en) | 1994-04-14 |
JPH08502068A (en) | 1996-03-05 |
CA2145681A1 (en) | 1994-04-14 |
KR950703347A (en) | 1995-09-20 |
EP0661982A1 (en) | 1995-07-12 |
NZ256178A (en) | 1997-03-24 |
ZA936978B (en) | 1994-04-18 |
NO951163D0 (en) | 1995-03-27 |
MX9305933A (en) | 1994-04-29 |
HUT70192A (en) | 1995-09-28 |
AU670962B2 (en) | 1996-08-08 |
NO951163L (en) | 1995-03-27 |
IL107066A0 (en) | 1993-12-28 |
HU9500891D0 (en) | 1995-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Silveira et al. | Putative M2 muscarinic receptors of rat heart have high affinity for organophosphorus anticholinesterases | |
Arnt et al. | Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI | |
Akera | Membrane Adenosinetriphosphatase: A Digitalis Receptor? The enzyme is a good model for receptor binding studies because of its known functional correlates. | |
TWI268923B (en) | N6 heterocyclic 8-modified adenosine derivatives | |
US7501436B2 (en) | 5-HT3 receptor antagonists and methods of use | |
US5204329A (en) | Treatment of organ transplantation rejection | |
IL107066A (en) | Pharmaceutical compositions containing diaminobenzenedisulfonic acid sodium salt oligomers for antagonizing inositol 1, 4, 5-triphosphate | |
CA2194277A1 (en) | Canptothecin drug combinations and medicaments with reduced side effects | |
CN104470941A (en) | Targeted therapeutics | |
WO2002015905A1 (en) | The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity | |
Allison et al. | Inhibition of the effect of lithium on brain inositol by atropine and scopolamine | |
TW201922246A (en) | Treatment of focal segmental glomerulosclerosis with CCR2 antagonists | |
US20050043327A1 (en) | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | |
Chakravarty et al. | A highly potent, orally active imidazo [4, 5-b] pyridine biphenyl acylsulfonamide (MK-996; L-159,282): A new AT1-selective angiotensin II receptor antagonist | |
JPH07502737A (en) | Heterocyclic compounds and their preparation and use | |
US20130338372A1 (en) | Substituted Imidazoline Compounds | |
Ahlijanian et al. | Antagonism of calmodulin-stimulated adenylate cyclase by trifluoperazine, calmidazolium and W-7 in rat cerebellar membranes. | |
JP2565762B2 (en) | Synthesis of glucagon analogues and their therapeutic use | |
PT1560830E (en) | Derivatives of [6, 7-dihydro-5h-imidazo[1,2 - a]imidazole -3 -sulfonylamino]-propionamide and their use as inhibitors upon the interaction of cams and leukointegrins | |
Way | Opioid tolerance and physical dependence and their relationship | |
WO2002050080A1 (en) | Small molecules useful in the treatment of inflammatory disease | |
JP2003512607A (en) | Allosteric site of muscarinic receptor | |
McQuade et al. | Characterization of the radioiodinated analogue of SCH 23390: in vitro and in vivo D-1 dopamine receptor binding studies | |
Liebmann et al. | Pharmacological and molecular actions of the bradykinin B2 receptor antagonist, Hoe 140, in the rat uterus | |
Akbulut et al. | Subtypes of muscarinic receptors in rat duodenum A comparison with rabbit vas deferens, rat atria, guinea-pig ileum and gallbladder by using imperialine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
RH | Patent void |